Current state of immunotherapy for glioblastoma

  title={Current state of immunotherapy for glioblastoma},
  author={Michael Lim and Yuanxuan Xia and Chetan Bettegowda and Michael Weller},
  journal={Nature Reviews Clinical Oncology},
Glioma is the most common primary cancer of the central nervous system, and around 50% of patients present with the most aggressive form of the disease, glioblastoma. Conventional therapies, including surgery, radiotherapy, and pharmacotherapy (typically chemotherapy with temozolomide), have not resulted in major improvements in the survival outcomes of patients with glioblastoma. Reasons for this lack of progress include invasive tumour growth in an essential organ, which limits the utility of… 

Targeting Glioblastoma: Advances in Drug Delivery and Novel Therapeutic Approaches

Glioblastoma (GB) is the most lethal type of primary tumor in the central nervous system. Current treatments include surgical resection followed by chemotherapy and radiotherapy. With this

Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development

The glioblastoma characteristics that drive tolerance to immunotherapy, the currently used immunotherapeutic approaches against gliablastoma, and the most suitable tumor models to mimic conditions in gliOBlastoma patients are summarized.

Immunotherapy Resistance in Glioblastoma

Insights gained from the studies summarized here may help pave the way for novel therapies to overcome barriers that have thus far limited the success of immunotherapy in glioblastoma.

The current state of immunotherapy for primary and secondary brain tumors: similarities and differences.

This review aims to briefly inform clinicians in the field of neuro-oncology on the relevant aspects of the immune system as it pertains to the central nervous system, with special focus on the differing modes of antigen presentation and tumor microenvironment of primary and metastatic brain tumors and the role these differences may play in the efficacy of immunotherapy in eradicating the tumor.

Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells

New insights are provided into the application of different medications in combination to boost the host immune system to interfere with immune evasion of glioblastoma cells which are promising prerequisites for therapeutic approaches to treat gliOBlastoma patients.

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma

The recent success of checkpoint blockade therapy, targeting immunoinhibitory proteins such as programmed cell death protein-1 and/or cytotoxic T lymphocyte-associated antigen-4, has initiated a paradigm shift in clinical and preclinical investigations, and the use of immunotherapy for solid tumors, which would be a potential breakthrough in the field of drug therapy for the GBM treatment.

The Path Toward PET-Guided Radiation Therapy for Glioblastoma in Laboratory Animals: A Mini Review

The aim of this review is to give a brief overview of promising PET tracers that can be evaluated in laboratory animals to bridge the gap between PET-based dose painting in glioblastoma patients.

The current and future aspects of glioblastoma: Immunotherapy a new hope?

It is believed that immunotherapy could result in a significantly more stable reaction in GBM patients and the feasibility of the future of personalized vaccine of nanomedicine‐based immunotherapies for the brain tumor is explored.

Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives

The potential of current immunotherapy modalities for glioblastoma treatment, especially focusing on major immune checkpoint inhibitors and the future strategies with novel targets and combo therapies are explored.

Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions

Developing strategies to overcome challenges will be necessary to accelerate the transition of CAR-T cell immunotherapy against GBMs from bench to bedside and face several challenges, such as tumor heterogeneity, tumor immunosuppressive microenvironment, and CAR- T cell persistence.



Prospects of immune checkpoint modulators in the treatment of glioblastoma

Challenges that need to be considered in the clinical development of drugs that target immune checkpoint pathways in glioblastoma, such as specific properties of the immune system in the CNS, issues with radiological response assessment, and potential interactions with established and emerging treatment strategies are discussed.

Immunosuppressive mechanisms in glioblastoma.

There is a persistent challenge for the use of immune therapy to treat glioblastoma secondary to the existence of redundant mechanisms of tumor-mediated immune suppression, and mechanisms of immunosuppression are addressed.

Oncolytic Virotherapy for the Treatment of Malignant Glioma

Despite the 25 years that has passed since the initial publication of genetically engineered oncolytic viruses for the treatment of glioma, much remains to be learned about this therapy, including its mechanism of action, optimal treatment paradigm, appropriate targets, and integration with adjuvant agents.

Issues to Consider in Designing Immunotherapy Clinical Trials for Glioblastoma Management

Glioblastoma (GBM) is the most common primary brain malignancy in adults and has a poor prognosis despite standard of care treatment. The mainstay of GBM treatment has relied on maximum surgical

Vaccine-based immunotherapeutic approaches to gliomas and beyond

Preclinical trial data suggest that addition of immunomodulatory reagents such as immune checkpoint inhibitors, transforming growth factor-β inhibitors, signal transducer and activator of transcription 3 inhibitors, or modifiers of tryptophan metabolism could augment the therapeutic activity of vaccination and overcome glioma-associated immunosuppression.

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

The roles of VEGF and ANG2 are outlined, and ways that antiangiogenic agents can be combined with immune-checkpoint inhibitors to potentially improve patient outcomes are suggested, and avenues of future research are highlighted.

Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

  • J. ZengA. See M. Lim
  • Medicine, Biology
    International journal of radiation oncology, biology, physics
  • 2013

Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma.

An overview of three important themes in the central nervous system anti-tumor immunity--i.e., antigen expression, how antigen may be presented, and lymphocyte trafficking--and subsequently discuss the extant work on TILs in glioma are provided.

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

The results support prioritizing the clinical evaluation of PD-1, PD-L1, and CTLA-4 single-agent targeted therapy as well as combination therapy of CTla-4 plusPD-1 blockade for patients with glioblastoma.

Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

It is shown that LC combined with anti-programmed cell death protein 1 (PD-1) facilitates an antitumor immune response and improves survival in glioblastoma and this study suggests that both mode of delivery and timing have distinct effects on the efficacy of anti- PD-1.